Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
AI Chat Bot for Websites
sajith.xp.pk
Updated:
Thursday at 1:17 PM
Puffin Rock Characters Plush Toy Set
anil1961
Updated:
Nov 7, 2026
Toyota Vitz scp10 For Sale
Lakmal Bandara
Updated:
Nov 4, 2026
Kandy
Welcome all my all new pet shop Bark.lk
dilumrane
Updated:
Nov 2, 2026
Windows RDP Only Rs.500 a month
Blogerwiki
Updated:
Nov 1, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
ElaKiri.com
News and Updates
Novel antibody offers pan-coronavirus protection.
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 26103968" data-attributes="member: 562115"><p>Adagio Therapeutics claims that that its ADG-2 antibody candidate offered strong potency against SARS-CoV-2, as well as a range of pre-emergent coronaviruses.</p><p>In in vitro and in vivo test results published January 25, ADG2 was found to bind to all known variants of SARS-CoV-2 and a range of sarbecoviruses that pose a threat to humans. </p><p></p><p>Additionally, ADG2 yielded protective efficacy in mouse models of SARS and COVID-19 and offered similar or higher potency against SARS-CoV-2 compared with other monoclonal antibodies in development or approved for emergency use.</p><p></p><p>ADG2, which was able to completely protect mice against severe SARS-CoV-2 and SARS-CoV when they were treated prophylactically. It was able to bind to more than 30 of the most frequently observed SARS-CoV-2 variants, including those resistant to other mAbs in development or approved for emergency use, and more than a dozen sarbecoviruses receptor binding domains.</p><p></p><p>Adagio said that ADG20 -- its half-life engineered version of ADG2 -- could offer protection against COVID-19 for up to a year. ADG20 is expected to enter phase I clinical studies in early 2021.</p></blockquote><p></p>
[QUOTE="imhotep, post: 26103968, member: 562115"] Adagio Therapeutics claims that that its ADG-2 antibody candidate offered strong potency against SARS-CoV-2, as well as a range of pre-emergent coronaviruses. In in vitro and in vivo test results published January 25, ADG2 was found to bind to all known variants of SARS-CoV-2 and a range of sarbecoviruses that pose a threat to humans. Additionally, ADG2 yielded protective efficacy in mouse models of SARS and COVID-19 and offered similar or higher potency against SARS-CoV-2 compared with other monoclonal antibodies in development or approved for emergency use. ADG2, which was able to completely protect mice against severe SARS-CoV-2 and SARS-CoV when they were treated prophylactically. It was able to bind to more than 30 of the most frequently observed SARS-CoV-2 variants, including those resistant to other mAbs in development or approved for emergency use, and more than a dozen sarbecoviruses receptor binding domains. Adagio said that ADG20 -- its half-life engineered version of ADG2 -- could offer protection against COVID-19 for up to a year. ADG20 is expected to enter phase I clinical studies in early 2021. [/QUOTE]
Insert quotes…
Verification
Hath warak paha keeyada? (hatha wadikireema paha)
Post reply
Top
Bottom